MARLBOROUGH, Mass.,
April 18, 2016 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a
clinical-stage RNAi company developing innovative therapeutics in
dermatology and ophthalmology that address significant unmet
medical needs, announced today that it will present at the
Association for Research in Vision and Ophthalmology (ARVO) 2016
annual meeting. This meeting is the largest gathering of eye
and vision researchers in the world drawing 11,000 attendees
exploring cutting-edge science. This year's conference will be held
May 1-5, 2016 at the Washington State Convention Center in
Seattle, Washington.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
On Sunday, May 1, 2016, new data
from ongoing research utilizing the Company's proprietary RNAi
platform in the area of therapeutic topical delivery to the eye,
will be presented in the 3:15 – 5:00 p.m.
PDT poster session: Corneal Wound Repair and Healing.
These data may be viewed on Poster 1280 - D0228 entitled,
"sd-rxRNA®: Self-Delivering RNAi Compounds Show Potential for
Corneal Indications Following Topical Application."
The poster will be available under the "Investors –
Presentations & Posters" section of the Company's
website, www.rxipharma.com approximately 1 hour following
the presentation.
About RXi's Proprietary Self-delivering RNAi (sd-rxRNA®)
Platform
Building on the pioneering work of Dr. Craig Mello, Nobel Laureate and RXi's Scientific
Advisory Board Chairman, scientists at RXi developed novel sd-rxRNA
compounds where drug-like properties are built into the RNAi
compound itself. These proprietary compounds are novel RNAi
compounds with enhanced properties for therapeutic use
including: efficient spontaneous cellular uptake, stability,
reduced potential for immune stimulation, and potent, long-lasting
intracellular activity. All cell types tested (primary,
neuronal and non-adherent) internalize sd-rxRNA compounds uniformly
and efficiently, resulting in potent and long lasting
silencing. Efficient cellular uptake is observed both in
vitro and in vivo, as well as in tissues including skin,
retina, lung, spinal cord and liver.
RXI-109, an sd-rxRNA compound designed to silence connective
tissue growth factor (CTGF), which plays a key role in tissue
regeneration and repair, is currently being evaluated in clinical
trials. A Phase 1/2 clinical study, RXI-109-1501, is underway
to evaluate the safety and clinical activity of RXI-109 to prevent
the progression of retinal scarring, a harmful component of
numerous retinal diseases. In addition, a Phase 2 clinical trial,
RXI-109-1402, is currently evaluating RXI-109 as a treatment to
reduce the recurrence of hypertrophic scars following scar revision
surgery. Over 100 subjects have been treated with RXI-109 by
intradermal injection in all trials to date. Multiple intradermal
injections were well tolerated at all dose levels. RXI-109
was shown to cause a dose-dependent silencing of CTGF messenger RNA
and protein levels in the treated areas of the skin compared to
placebo and preliminary results from Phase 2a studies indicate a
clinical effect on scar appearance.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage RNAi company developing innovative therapeutics in
dermatology and ophthalmology that address significant unmet
medical needs. Building on the pioneering work of RXi's
Scientific Advisory Board Chairman and Nobel Laureate Dr.
Craig Mello, our discovery and
clinical development programs are based on our proprietary RNAi
(sd-rxRNA) platform and Samcyprone™, a topical
immunomodulator. Our clinical development programs include RXI-109,
an sd-rxRNA, for the treatment of dermal and ocular scarring, and
Samcyprone™ for the treatment of such disorders as
warts, alopecia areata, non-malignant skin tumors and cutaneous
metastases of melanoma. RXi's robust pipeline, coupled with
an extensive patent portfolio, provides for multiple product and
business development opportunities across a broad spectrum of
therapeutic areas. We are committed to being a partner of choice
for academia, small companies, and large multinationals. We welcome
ideas and proposals for strategic alliances, including in- and
out-licensing opportunities, to advance and further develop
strategic areas of interest. Additional information may be found on
the Company's website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-association-for-research-in-vision-and-ophthalmology-2016-annual-meeting-300252561.html
SOURCE RXi Pharmaceuticals Corporation